Get the Stockscreener App
4.41
5.76%
0.24
After Hours:
4.50
0.09
+2.04%
Artiva Biotherapeutics Inc stock is traded at $4.41, with a volume of 181.60K.
It is up +5.76% in the last 24 hours and up +31.25% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$4.17
Open:
$4.13
24h Volume:
181.60K
Relative Volume:
0.07
Market Cap:
$108.24M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.50%
1M Performance:
+31.25%
6M Performance:
+173.91%
1Y Performance:
-58.40%
1-Day Range:
$4.13
$4.50
1-Week Range:
$4.10
$4.50
52-Week Range:
$1.47
$11.55
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
4.41 | 102.35M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Genelux Corporation Announces Appointment of Jason Litten as Chief Medical Officer, Effective January 2, 2026 - marketscreener.com
Will Artiva Biotherapeutics Inc. stock gain from lower inflationJuly 2025 Levels & Risk Controlled Swing Alerts - Улправда
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO’s Latest Insider Share Sale - Yahoo Finance
Will Artiva Biotherapeutics Inc. stock deliver long term returnsMarket Risk Summary & Reliable Entry Point Alerts - Улправда
Artiva Biotherapeutics Reports Increased Losses Amid Ongoing Development - MSN
Is Artiva Biotherapeutics Inc. stock undervalued vs historical averagesJuly 2025 PreEarnings & Technical Pattern Based Signals - DonanımHaber
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) dropped from NASDAQ Biotechnology Index - marketscreener.com
CEO Moves: Can Artiva Biotherapeutics Inc. stock rebound after recent weakness2025 Big Picture & High Accuracy Swing Entry Alerts - Улправда
Can Artiva Biotherapeutics Inc. stock rebound after recent weaknessJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - Улправда
Resistance Check: Can Artiva Biotherapeutics Inc. stock rebound after recent weaknessDividend Hike & Free Safe Entry Trade Signal Reports - Улправда
ARTV Stock Price and Chart — NASDAQ:ARTV - TradingView — Track All Markets
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Artiva Biotherapeutics CEO sells $19,122 in stock By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Artiva Biotherapeutics (ARTV) Stock: Today’s News (Dec. 16, 2025), Why Shares Spiked, Analyst Forecasts, and What Investors Are Watching Next - ts2.tech
Insider Sell: Fred Aslan Sells Shares of Artiva Biotherapeutics Inc (ARTV) - GuruFocus
Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells 3,187 Shares of Stock - MarketBeat
Artiva Biotherapeutics CEO sells $19,122 in stock - Investing.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
US Stocks Mixed; NY Manufacturing Activity Dips In December - Benzinga
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Artiva Biotherapeutics Executes RSU Exchange for Employees - TipRanks
Artiva Biotherapeutics Advances with Promising NK Cell Therapy Study - MSN
Artiva Biotherapeutics executes RSU exchange for employees - MSN
Pre Market Movers: XCUR, VOR, MTVA Set The Path - RTTNews
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Nurix Therapeutics (NRIX) - The Globe and Mail
How Artiva Biotherapeutics Inc. stock trades before earningsPortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - Newser
Will Artiva Biotherapeutics Inc. stock outperform tech sector in 2025Trade Exit Report & Consistent Profit Trading Strategies - Newser
Risk Hedge: Can Artiva Biotherapeutics Inc. stock rebound after recent weakness2025 Institutional Moves & Daily Growth Stock Tips - moha.gov.vn
A new trading data show Allarity Therapeutics Inc (ALLR) is showing positive returns. - Setenews
Analysts Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $19.00 - Defense World
Artiva Biotherapeutics (ARTV) Stock Analysis Report | Financials & Insights - Benzinga
LNP | LancasterOnline Events3rd Cell Therapy for Autoimmune Disease Summit - LancasterOnline
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why Artiva Biotherapeutics Inc. stock is seen as undervalued2025 Risk Factors & Reliable Momentum Entry Alerts - newser.com
Will Artiva Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - newser.com
How resilient is Artiva Biotherapeutics Inc. stock in market downturnsWeekly Investment Report & Expert Curated Trade Ideas - newser.com
Is Artiva Biotherapeutics Inc. stock attractive for retirement portfoliosWeekly Market Report & Weekly Consistent Profit Watchlists - newser.com
Why Artiva Biotherapeutics Inc. stock could rally in 2025 - newser.com
Artiva Biotherapeutics Inc. stock daily chart insights2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Is Artiva Biotherapeutics Inc. stock supported by strong cash flows2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
ARTV: Off-the-shelf NK cell therapy for autoimmune disease advances toward pivotal RA trial with strong safety and funding - TradingView
Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $21,547.50 in Stock - MarketBeat
Relative strength of Artiva Biotherapeutics Inc. in sector analysisSwing Trade & Free Weekly Watchlist of Top Performers - newser.com
Aslan Fred sells Artiva Biotherapeutics (ARTV) stock for $21,522 By Investing.com - Investing.com UK
Aslan Fred sells Artiva Biotherapeutics (ARTV) stock for $21,522 - Investing.com India
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
There is no financial data for Artiva Biotherapeutics Inc (ARTV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):